Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MannKind Corp MNKD

Healthcare Biotechnology
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the... see more

Recent & Breaking News (NDAQ:MNKD)

MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

GlobeNewswire January 5, 2022

MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

GlobeNewswire December 6, 2021

MannKind Corporation Reports 2021 Third Quarter Financial Results

GlobeNewswire November 9, 2021

Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

GlobeNewswire November 9, 2021

MannKind Presents Data at 21st Annual Diabetes Technology Meeting

GlobeNewswire November 5, 2021

MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021

GlobeNewswire November 2, 2021

Progress Update on Tyvaso DPI(TM) New Drug Application

GlobeNewswire October 18, 2021

MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza® in Pediatric Population

GlobeNewswire October 4, 2021

Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

GlobeNewswire September 29, 2021

MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

GlobeNewswire September 28, 2021

Mannkind Corporation Participating at Upcoming Conferences

GlobeNewswire September 15, 2021

MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

United Therapeutics Presents Tyvaso DPI(TM) BREEZE Clinical Data At The European Respiratory Society International Congress 2021

PR Newswire September 7, 2021

30 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 2, 2017

FDA Updates Afrezza® Prescribing Information

GlobeNewswire October 2, 2017

MannKind Corporation to Hold Investor Conference Call

GlobeNewswire October 1, 2017

MannKind Responds to Hurricane Harvey Devastation with Afrezza® Donation

GlobeNewswire September 7, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  September 7, 2017

MannKind Corporation Relocates Headquarters to Westlake Village

GlobeNewswire September 5, 2017

MannKind Corporation to Present at Upcoming Conferences

GlobeNewswire September 1, 2017